Level I, therapeutic study. See the Guidelines for Authors for a complete description of levels of evidence.

Patellar resurfacing in total knee arthroplasty remains controversial. This study compared the long-term clinical outcomes of total knee arthroplasties performed with and without the patella resurfaced and is an update of a previous report. Eighty-six patients (118 knees) underwent primary total knee replacement and were randomized into two groups: those treated with and those treated without resurfacing of the patella. Outcomes included the scores according to the Knee Society clinical rating system, the scores according to a forty-one-question patellofemoral-specific patient questionnaire, patient satisfaction, global and anterior knee pain scores, radiographic findings, and complications and revisions. Fifty-seven patients (seventy-eight knees) were followed for a minimum of ten years. No significant differences were identified between the two groups in terms of the range of motion, Knee Society scores, satisfaction, global knee pain, or anterior knee pain. The overall revision rates in the original series of 118 knees were 12% in the nonresurfacing group and 9% in the resurfacing group. Seven patients (12%) in the nonresurfacing group and two patients (3%) in the resurfacing group underwent revision for a reason related to a patellofemoral problem. On the basis of these findings, we concluded that, with the type of total knee arthroplasty used in our patients, similar results may be achieved with and without patellar resurfacing.

No abstract

The traditional treatment of a first-time anterior shoulder dislocation of reduction and a period of immobilisation should be challenged. The purpose of this review is to assimilate and present the current literature on acute anterior shoulder instability. This involves consideration of the pathoanatomy, natural history and the more recent evaluation of treatment outcomes, which appropriately incorporate quality of life measures in addition to recurrences. There is ample evidence to consider primary stabilisation as an option for treatment in the high-risk group, less than 25 years of age.

No abstract